GUANGZHOU, China
Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat, Celebrex, Cisplatin and CTLA-4, respectively. The presentation will be held in 2018 AACR in Chicago, USA. The details are as follows:
Title: Novel small molecule inhibitors of PD-1/PD-L1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel and Canonical Targets
Session Date and Time: Tuesday April 17, 2018 8:00am-12:00pm
Location: McCormick Place South, Exhibit Hall A, Poster Section 35
Poster Board Number: 17
Permanent Abstract Number: 3851
About Maxinovel Pharmaceuticals, Inc:
Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005313/en/
CONTACT
Maxinovel Pharmaceuticals
Ms. Pingjing Zhang
pjzhang@maxinovel.com
